Protagonist Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	60	26.58	27.36	28.63	0.23	30.93	20.06	0	0	0
Revenue Growth (YoY)	125.73%	-2.84%	-4.44%	12293.07%	-99.25%	54.14%	-	-	-	-
Gross Profit	60	26.58	27.36	28.63	0.23	30.93	20.06	0	0	0
Selling, General & Admin	33.49	31.74	27.2	18.64	15.75	13.7	11.78	6.96	2.96	1.86
Research & Development	120.16	126.22	126.01	74.51	65	59.5	46.18	25.71	11.83	7.46
Other Operating Expenses	0	0	0	0	0	0	0	0.03	0	0
Operating Expenses	153.65	157.95	153.2	93.14	80.75	73.19	57.96	32.7	14.79	9.32
Operating Income	-93.65	-131.37	-125.85	-64.52	-80.52	-42.27	-37.9	-32.7	-14.79	-9.32
Interest Expense / Income	0	0	0	0.6	0.17	0	0	0	0	0
Other Expense / Income	-14.7	-3.98	-0.29	-0.27	-2.81	-2.55	-0.94	5.04	0.14	1.9
Pretax Income	-78.96	-127.39	-125.55	-64.85	-77.88	-39.72	-36.96	-37.74	-14.93	-11.22
Income Tax	0	0	0	1.31	-0.69	-0.8	0	0	0	0
Net Income	-78.96	-127.39	-125.55	-66.15	-77.19	-38.92	-36.96	-37.74	-14.93	-11.22
Shares Outstanding (Basic)	57	49	46	34	26	22	18	7	0	0
Shares Outstanding (Diluted)	57	49	46	34	26	22	18	7	0	0
Shares Change	15.74%	5.87%	34.67%	32.84%	15.78%	26.39%	172.15%	2482.98%	10.79%	-
EPS (Basic)	-1.39	-2.60	-2.71	-1.92	-2.98	-1.74	-2.09	-5.80	-59.32	-49.38
EPS (Diluted)	-1.39	-2.60	-2.71	-1.92	-2.98	-1.74	-2.09	-5.80	-59.32	-49.38
Free Cash Flow	-70.85	-108.93	-108.97	-72.96	-42.49	-50.43	3.21	-30.32	-14.78	-8.04
Free Cash Flow Per Share	-1.25	-2.22	-2.35	-2.12	-1.64	-2.25	0.18	-4.66	-58.73	-35.40
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-	-	-
Operating Margin	-156.09%	-494.24%	-460.01%	-225.36%	-34857.58%	-136.68%	-188.89%	-	-	-
Profit Margin	-131.59%	-479.26%	-458.94%	-231.07%	-33414.29%	-125.87%	-184.20%	-	-	-
Free Cash Flow Margin	-118.08%	-409.81%	-398.31%	-254.84%	-18395.67%	-163.08%	15.98%	-	-	-
EBITDA	-75.64	-124.02	-122.78	-61.52	-75.19	-39.2	-36.55	-37.42	-14.69	-10.96
EBITDA Margin	-126.07%	-466.59%	-448.79%	-214.91%	-32547.62%	-126.75%	-182.18%	-	-	-
Depreciation & Amortization	3.31	3.37	2.78	2.72	2.52	0.53	0.41	0.32	0.25	0.26
EBIT	-78.96	-127.39	-125.55	-64.25	-77.71	-39.72	-36.96	-37.74	-14.93	-11.22
EBIT Margin	-131.59%	-479.26%	-458.94%	-224.42%	-33640.26%	-128.45%	-184.20%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).